The role is reviewed of sulphasalazine, 5‐aminosalicylic acid (5‐ASA), immunosup‐pressive agents and corticosteroids in the maintenance treatment of ulcerative colitis in remission. Sulphasalazine and oral 5‐ASA are the drugs of first choice in preventing relapses for patients suffering from intermittent chronic ulcerative colitis. Rectally administered 5‐ASA may be a valid alternative for treating patients with proctitis and left‐sided ulcerative colitis. The optimal dosage of oral 5‐ASA in the maintenance therapy of ulcerative colitis in remission is not clear. However, there is evidence that a higher dose of 5‐ASA is more effective than low dosage in preventing relapses in patients in remission. For patients with chronically active or steroid‐dependent ulcerative colitis who have achieved remission while taking immunosup‐pressants, continuing azathioprine or 6‐mercaptopurine is indicated. Existing data cast doubts as to whether or not continuous maintenance is still necessary in patients suffering from intermittent chronic ulcerative colitis with prolonged endoscopic, clinical and histological remission.
European Journal of Gastroenterology & Hepatology – Wolters Kluwer Health
Published: Sep 1, 1997
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud